Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
Status:
Completed
Trial end date:
2010-09-20
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the long-term safety and tolerability of the subcutaneous
(SC) injection form of N-methylnaltrexone bromide (MOA-728) for the treatment of
opioid-induced constipation in participants with nonmalignant pain. The study consists of a
2-week screening period, a 48-week open-label treatment period and a 2 week follow-up period.
Participants will need to agree to self-administer SC injections, complete daily diaries, and
check-in via a daily telephone call during the study.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.